: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

The Angels Initiative

Stroke prevention

Prostate Cancer

Free Subscription

Articles published in Prostate
Retrieve available abstracts of 333 articles:
HTML format

Single Articles

August 2022

WANG S, Ryan Russell J, Drescher M, Park A, et al
Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.
Prostate. 2022 Aug 3. doi: 10.1002/pros.24425.
PubMed Abstract available

LOMBARDO R, Rovesti L, Cicione A, Gravina C, et al
Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort.
Prostate. 2022 Aug 3. doi: 10.1002/pros.24412.
PubMed Abstract available

KWAN EM, Wyatt AW
Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
Prostate. 2022;82 Suppl 1:S25-S36.
PubMed Abstract available

SUTERA P, Deek MP, Van der Eecken K, Wyatt AW, et al
Genomic biomarkers to guide precision radiotherapy in prostate cancer.
Prostate. 2022;82 Suppl 1:S73-S85.
PubMed Abstract available

KHAN HM, Cheng HH
Germline genetics of prostate cancer.
Prostate. 2022;82 Suppl 1:S3-S12.
PubMed Abstract available

CRESTA MORGADO P, Mateo J
Clinical implications of homologous recombination repair mutations in prostate cancer.
Prostate. 2022;82 Suppl 1:S45-S59.
PubMed Abstract available

COTTER K, Rubin MA
The evolving landscape of prostate cancer somatic mutations.
Prostate. 2022;82 Suppl 1:S13-S24.
PubMed Abstract available

ANTONARAKIS ES
Genetics and genomics of prostate cancer and therapeutic implications.
Prostate. 2022;82 Suppl 1:S1-S2.
PubMed

MIZUNO K, Beltran H
Future directions for precision oncology in prostate cancer.
Prostate. 2022;82 Suppl 1:S86-S96.
PubMed Abstract available

CHOUDHURY AD
PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
Prostate. 2022;82 Suppl 1:S60-S72.
PubMed Abstract available

LI G, Xia YF, Huang YX, Okat D, et al
Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost-effective?
Prostate. 2022 Aug 1. doi: 10.1002/pros.24417.
PubMed Abstract available

UCAR T, Gunduz N, Demirci E, Culpan M, et al
Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
Prostate. 2022 Aug 1. doi: 10.1002/pros.24420.
PubMed Abstract available

July 2022

YAZGAN SC, Yekeduz E, Utkan G, Urun Y, et al
Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
Prostate. 2022 Jul 28. doi: 10.1002/pros.24419.
PubMed Abstract available

KHAN S, Vohra S, Farnan L, Elmore SNC, et al
Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.
Prostate. 2022 Jul 26. doi: 10.1002/pros.24418.
PubMed Abstract available

WANG Y, Tang Y, Gao X, Gan Y, et al
Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and (68) Ga-PSMA-PET-derived SUVmax values.
Prostate. 2022 Jul 21. doi: 10.1002/pros.24415.
PubMed Abstract available

MIYAHIRA AK, Soule HR
The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
Prostate. 2022 Jul 18. doi: 10.1002/pros.24409.
PubMed Abstract available

MODONUTTI D, Majdalany SE, Corsi N, Li P, et al
A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis.
Prostate. 2022 Jul 5. doi: 10.1002/pros.24403.
PubMed Abstract available

RAMIREZ-TORRES A, Reagan AL, Howard LE, Wiggins E, et al
Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.
Prostate. 2022 Jul 5. doi: 10.1002/pros.24398.
PubMed Abstract available

June 2022

YANAGISAWA T, Kimura T, Hata K, Narita S, et al
Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
Prostate. 2022 Jun 29. doi: 10.1002/pros.24406.
PubMed Abstract available

CASADO-LLOMBART S, Ajami T, Consuegra-Fernandez M, Carreras E, et al
Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
Prostate. 2022 Jun 29. doi: 10.1002/pros.24407.
PubMed Abstract available

BRAY AW, Duan R, Malalur P, Drusbosky LM, et al
Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Prostate. 2022 Jun 29. doi: 10.1002/pros.24400.
PubMed Abstract available

MIURA Y, Hatakeyama S, Narita S, Kimura T, et al
Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Prostate. 2022 Jun 23. doi: 10.1002/pros.24404.
PubMed Abstract available

YANG T, Liu Y, Chen S, Tian J, et al
Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
Prostate. 2022 Jun 23. doi: 10.1002/pros.24402.
PubMed Abstract available

HEARD JR, Huang AJ, Werle L, Adler K, et al
Definitive treatment choice among Black immigrants with prostate cancer: Analysis of patient surveys distributed at a single safety-net institution.
Prostate. 2022 Jun 23. doi: 10.1002/pros.24399.
PubMed Abstract available

STENZL A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, et al
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Prostate. 2022 Jun 8. doi: 10.1002/pros.24396.
PubMed Abstract available

LIU AJ, Kosiorek HE, Ueberroth BE, Jaeger E, et al
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Prostate. 2022 Jun 2. doi: 10.1002/pros.24375.
PubMed Abstract available

SORCE G, Hoeh B, Flammia RS, Chierigo F, et al
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.
Prostate. 2022 Jun 2. doi: 10.1002/pros.24376.
PubMed Abstract available

CHO HL, Murthy V, Mouw KW, D'Amico AV, et al
Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy.
Prostate. 2022 Jun 2. doi: 10.1002/pros.24362.
PubMed Abstract available

ABDI B, Basset N, Perrot E, Benderra MA, et al
DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
Prostate. 2022 Jun 2. doi: 10.1002/pros.24374.
PubMed Abstract available

MUNOZ-MORENO L, Carmena MJ, Prieto JC, Schally AV, et al
Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
Prostate. 2022;82:933-941.
PubMed Abstract available

FUJIWARA M, Numao N, Yamamoto S, Ishikawa Y, et al
Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy.
Prostate. 2022;82:904-910.
PubMed Abstract available

HOLZE S, Lemaire E, Mende M, Neuhaus P, et al
Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).
Prostate. 2022;82:894-903.
PubMed Abstract available

RATNANI P, Dovey Z, Parekh S, Sobotka S, et al
Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
Prostate. 2022;82:970-983.
PubMed Abstract available

May 2022

ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
Prostate. 2022 May 17. doi: 10.1002/pros.24366.
PubMed Abstract available

PELLEGRINO F, Stabile A, Mazzone E, Sorce G, et al
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
Prostate. 2022 May 10. doi: 10.1002/pros.24368.
PubMed Abstract available

HE Y, Shen Q, Fu W, Wang H, et al
Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
Prostate. 2022 May 10. doi: 10.1002/pros.24365.
PubMed Abstract available

MORGANS AK, Chen YH, Jarrard DF, Carducci M, et al
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Prostate. 2022 May 10. doi: 10.1002/pros.24369.
PubMed Abstract available

SAKELLAKIS M
Orphan receptors in prostate cancer.
Prostate. 2022 May 10. doi: 10.1002/pros.24370.
PubMed Abstract available

KEEGAN NM, Vasselman SE, Barnett ES, Nweji B, et al
Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
Prostate. 2022 May 10. doi: 10.1002/pros.24363.
PubMed Abstract available

DENMEADE S, Antonarakis ES, Markowski MC
Bipolar androgen therapy (BAT): A patient's guide.
Prostate. 2022;82:753-762.
PubMed Abstract available

VITEK RA, Huang W, Geiger PG, Heninger E, et al
Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment.
Prostate. 2022;82:836-849.
PubMed Abstract available

LUNACEK A, Tischler M, Mrstik C, Hebenstreit D, et al
Effects of cycling and rowing on serum concentrations of prostate-specific antigen: A randomized study of 101 male subjects.
Prostate. 2022;82:804-808.
PubMed Abstract available

April 2022

BOSLAND MC, Horton L, Condon MS
Effects of green tea on prostate carcinogenesis in rat models and a human prostate cancer xenograft model.
Prostate. 2022 Apr 29. doi: 10.1002/pros.24364.
PubMed Abstract available

WITHROW D, Pilleron S, Nikita N, Ferlay J, et al
Current and projected number of years of life lost due to prostate cancer: A global study.
Prostate. 2022 Apr 25. doi: 10.1002/pros.24360.
PubMed Abstract available

WANG M, Qi J, George AK, Semerjian A, et al
The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
Prostate. 2022 Apr 25. doi: 10.1002/pros.24357.
PubMed Abstract available

HU Q, Hong X, Xu L, Jia R, et al
A nomogram for accurately predicting the pathological upgrading of prostate cancer, based on (68) Ga-PSMA PET/CT.
Prostate. 2022 Apr 25. doi: 10.1002/pros.24358.
PubMed Abstract available

YUEN KC, Tran B, Anton A, Hamidi H, et al
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
Prostate. 2022 Apr 18. doi: 10.1002/pros.24346.
PubMed Abstract available

PITAK-ARNNOP P, Messer-Peti R, Tangmanee C, Neff A, et al
Prostate cancer awareness among transgender women after gender-affirming surgery.
Prostate. 2022 Apr 13. doi: 10.1002/pros.24355.
PubMed Abstract available

MORI JO, Shafran JS, Stojanova M, Katz MH, et al
Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.
Prostate. 2022 Apr 11. doi: 10.1002/pros.24351.
PubMed Abstract available

FLAMMIA RS, Hoeh B, Sorce G, Chierigo F, et al
Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients.
Prostate. 2022 Apr 11. doi: 10.1002/pros.24350.
PubMed Abstract available

LV X, Li Y, Li R, Guan X, et al
Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants.
Prostate. 2022 Apr 11. doi: 10.1002/pros.24345.
PubMed Abstract available

SORCE G, Flammia RS, Hoeh B, Chierigo F, et al
Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
Prostate. 2022 Apr 1. doi: 10.1002/pros.24349.
PubMed Abstract available

YAMAGUCHI M, Murata T, Ramos JW
Overexpression of regucalcin blocks the migration, invasion, and bone metastatic activity of human prostate cancer cells: Crosstalk between cancer cells and bone cells.
Prostate. 2022 Apr 1. doi: 10.1002/pros.24348.
PubMed Abstract available

ZHOU Z, Liang Z, Zuo Y, Zhou Y, et al
Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Prostate. 2022;82:556-565.
PubMed Abstract available

CHEN Z, Wu J, Sun K, He Y, et al
Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy.
Prostate. 2022;82:566-575.
PubMed Abstract available

LINDH C, Samaratunga H, Delahunt B, Bergstrom R, et al
Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
Prostate. 2022;82:576-583.
PubMed Abstract available

WEI X, Roudier MP, Kwon OJ, Lee JD, et al
Paracrine Wnt signaling is necessary for prostate epithelial proliferation.
Prostate. 2022;82:517-530.
PubMed Abstract available

March 2022

GRAHAM LS, Schweizer MT
Mismatch repair deficiency and clinical implications in prostate cancer.
Prostate. 2022 Mar 31. doi: 10.1002/pros.24343.
PubMed Abstract available

PREISSER F, Heinze A, S Abrams-Pompe R, Budaus L, et al
Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.
Prostate. 2022 Mar 28. doi: 10.1002/pros.24341.
PubMed Abstract available

SINGH CK, Denu RA, Nihal M, Shabbir M, et al
PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.
Prostate. 2022 Mar 25. doi: 10.1002/pros.24342.
PubMed Abstract available

MAO F, Kong Y, Liu J, Rao X, et al
Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.
Prostate. 2022 Mar 24. doi: 10.1002/pros.24336.
PubMed Abstract available

LUNDGREN PO, Tribukait B, Kjellman A, Norming U, et al
Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer.
Prostate. 2022 Mar 16. doi: 10.1002/pros.24335.
PubMed Abstract available

SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
(177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis.
Prostate. 2022 Mar 14. doi: 10.1002/pros.24325.
PubMed Abstract available

ZHANG T, Kephart J, Bronson E, Anand M, et al
Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
Prostate. 2022 Mar 14. doi: 10.1002/pros.24329.
PubMed Abstract available

ANTONARAKIS ES, Tierno M, Fisher V, Tukachinsky H, et al
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Prostate. 2022 Mar 14. doi: 10.1002/pros.24331.
PubMed Abstract available

SENTANA-LLEDO D, Sartor O, Balk SP, Einstein DJ, et al
Immune mechanisms behind prostate cancer in men of African ancestry: A review.
Prostate. 2022 Mar 7. doi: 10.1002/pros.24333.
PubMed Abstract available

BECKMANN KR, Bangma CH, Helleman J, Bjartell A, et al
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
Prostate. 2022 Mar 7. doi: 10.1002/pros.24330.
PubMed Abstract available

HINOJOSA-GONZALEZ DE, Roblesgil-Medrano A, Torres-Martinez M, Alanis-Garza C, et al
Single-port versus multiport robotic-assisted radical prostatectomy: A systematic review and meta-analysis on the da Vinci SP platform.
Prostate. 2022;82:405-414.
PubMed Abstract available

LEITSMANN C, Uhlig A, Bremmer F, Mut TT, et al
Impact of mpMRI targeted biopsy on intraoperative nerve-sparing (NeuroSAFE) during robot-assisted laparoscopic radical prostatectomy.
Prostate. 2022;82:493-501.
PubMed Abstract available

KOPARAL MY, Sozen TS, Karsiyakali N, Aslan G, et al
Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association.
Prostate. 2022;82:425-432.
PubMed Abstract available

February 2022

CHIERIGO F, Borghesi M, Wurnschimmel C, Flammia RS, et al
Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
Prostate. 2022 Feb 28. doi: 10.1002/pros.24317.
PubMed Abstract available

PURAYIL HT, Daaka Y
betaArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer.
Prostate. 2022 Feb 28. doi: 10.1002/pros.24324.
PubMed Abstract available

LIU JM, Chen YT, Wu CT, Hsu WL, et al
Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
Prostate. 2022 Feb 28. doi: 10.1002/pros.24323.
PubMed Abstract available

K C M, Oral E, Rung AL, Trapido EJ, et al
Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study.
Prostate. 2022 Feb 24. doi: 10.1002/pros.24320.
PubMed Abstract available

KANEKO M, Fukuda N, Nagano H, Yamada K, et al
Artificial intelligence trained with integration of multiparametric MR-US imaging data and fusion biopsy trajectory-proven pathology data for 3D prediction of prostate cancer: A proof-of-concept study.
Prostate. 2022 Feb 22. doi: 10.1002/pros.24321.
PubMed Abstract available

IZOL V, Ok F, Aslan G, Akdogan B, et al
Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
Prostate. 2022 Feb 21. doi: 10.1002/pros.24318.
PubMed Abstract available

OZBEK B, Ertunc O, Erickson A, Vidal ID, et al
Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer.
Prostate. 2022 Feb 21. doi: 10.1002/pros.24315.
PubMed Abstract available

HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
Prostate. 2022 Feb 21. doi: 10.1002/pros.24313.
PubMed Abstract available

HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.
Prostate. 2022 Feb 21. doi: 10.1002/pros.24312.
PubMed Abstract available

PAGEL CN, Kularathna PK, Sanaei R, Young ND, et al
Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
Prostate. 2022 Feb 15. doi: 10.1002/pros.24316.
PubMed Abstract available

WANG Y, Abenojar EC, Wang J, de Leon AC, et al
Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
Prostate. 2022 Feb 15. doi: 10.1002/pros.24314.
PubMed Abstract available

STAMIS SA, Heath EI, Lucas S, Boerner J, et al
Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
PubMed Abstract available

SUN Y, Ai JZ, Jin X, Liu LR, et al
IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
Prostate. 2022;82:401-402.
PubMed

URAKAMI A, Arimura H, Takayama Y, Kinoshita F, et al
Stratification of prostate cancer patients into low- and high-grade groups using multiparametric magnetic resonance radiomics with dynamic contrast-enhanced image joint histograms.
Prostate. 2022;82:330-344.
PubMed Abstract available

WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.
Prostate. 2022;82:399-400.
PubMed

HORSLEY PJ, Kneebone A, Eade TN, Hruby G, et al
Don't throw the baby out with the bath water.
Prostate. 2022;82:397-398.
PubMed

MA C, Downes M, Jain R, Ientilucci M, et al
Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
Prostate. 2022;82:345-351.
PubMed Abstract available

ZENNER ML, Helou YB, Deaton RJ, Sverdlov M, et al
Advanced glycation end-products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry.
Prostate. 2022;82:306-313.
PubMed Abstract available

ARCOT R, Cher ML, Qi J, Linsell SM, et al
Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
Prostate. 2022;82:323-329.
PubMed Abstract available

TAN YG, Fang AHS, Lim JKS, Khalid F, et al
Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy.
Prostate. 2022;82:298-305.
PubMed Abstract available

MA H, Xu W, Ni J, Zhao N, et al
Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
Prostate. 2022;82:276-285.
PubMed Abstract available

LI N, Song WJ, Gao J, Xu ZP, et al
The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot-assisted laparoscopic radical prostatectomy.
Prostate. 2022;82:221-226.
PubMed Abstract available

AUSSAVAVIROJEKUL P, Hoonlor A, Srinualnad S
Optimization of clinical risk-factor interpretation and radiological findings with machine learning for PIRADS category 3 patients.
Prostate. 2022;82:235-244.
PubMed Abstract available

SIEDOW M, Eisner M, Yaney A, Washington I, et al
Impact of prostate biopsy secondary pathology review on radiotherapy management.
Prostate. 2022;82:210-215.
PubMed Abstract available

January 2022

LUNA VELEZ MV, Paulino da Silva Filho O, Verhaegh GW, van Hooij O, et al
Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
Prostate. 2022 Jan 31. doi: 10.1002/pros.24309.
PubMed Abstract available

GARCIA-MARQUES F, Liu S, Totten SM, Bermudez A, et al
Protein signatures to distinguish aggressive from indolent prostate cancer.
Prostate. 2022 Jan 31. doi: 10.1002/pros.24307.
PubMed Abstract available

ZHAO R, Lv Y, Feng T, Zhang R, et al
ATF6alpha promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis.
Prostate. 2022 Jan 28. doi: 10.1002/pros.24308.
PubMed Abstract available

STOVER EH, Oh C, Keskula P, Choudhury AD, et al
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
Prostate. 2022 Jan 27. doi: 10.1002/pros.24305.
PubMed Abstract available

MOLL JM, Hofland J, Teubel WJ, de Ridder CMA, et al
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Prostate. 2022 Jan 17. doi: 10.1002/pros.24297.
PubMed Abstract available

ZHU S, Zhang Z, Zhang H, Liu Z, et al
DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
Prostate. 2022 Jan 17. doi: 10.1002/pros.24292.
PubMed Abstract available

ZHOU J, Chen H, Wu Y, Shi B, et al
Plasma IL-6 and TNF-alpha levels correlate significantly with grading changes in localized prostate cancer.
Prostate. 2022 Jan 17. doi: 10.1002/pros.24299.
PubMed Abstract available

CAO Y, Song DY, Deville C, DeWeese TL, et al
Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
Prostate. 2022 Jan 11. doi: 10.1002/pros.24301.
PubMed Abstract available

RASPIN K, O'Malley DE, Marthick JR, Donovan S, et al
Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
Prostate. 2022 Jan 7. doi: 10.1002/pros.24300.
PubMed Abstract available

VLACHOSTERGIOS PJ, Niaz MJ, Thomas C, Christos PJ, et al
Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
Prostate. 2022 Jan 5. doi: 10.1002/pros.24294.
PubMed Abstract available

SEREF C, Acar O, Kilic M, Vural M, et al
Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations.
Prostate. 2022;82:145-153.
PubMed Abstract available

YUAN W, Liu B, Sanda M, Wei R, et al
Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
Prostate. 2022;82:132-144.
PubMed Abstract available

WIDJAJA L, Derlin T, Ross TL, Bengel FM, et al
Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
Prostate. 2022;82:86-96.
PubMed Abstract available

December 2021

SNIPAITIENE K, Bakavicius A, Lazutka JR, Ulys A, et al
Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
Prostate. 2021 Dec 30. doi: 10.1002/pros.24293.
PubMed Abstract available

MIKOSHI A, Miyai K, Hamabe F, Edo H, et al
MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern.
Prostate. 2021 Dec 28. doi: 10.1002/pros.24291.
PubMed Abstract available

SIENKIEWICZ K, Yang C, Paschal BM, Ratan A, et al
Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
Prostate. 2021 Dec 24:e24290. doi: 10.1002/pros.24290.
PubMed Abstract available

HE H, Han D, Xu F, Lyu J, et al
How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
Prostate. 2021 Dec 20. doi: 10.1002/pros.24287.
PubMed Abstract available

URABE F, Miki K, Kimura T, Sasaki H, et al
Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
Prostate. 2021 Dec 16. doi: 10.1002/pros.24289.
PubMed Abstract available

KAUFMANN B, Saba K, Schmidli TS, Stutz S, et al
Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Prostate. 2021 Dec 16. doi: 10.1002/pros.24286.
PubMed Abstract available

BARLOW SK, Oyekunle T, Janes JL, De Hoedt AM, et al
Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
Prostate. 2021 Dec 14. doi: 10.1002/pros.24283.
PubMed Abstract available

LEFEBVRE F, Blanchet-Deverly A, Michineau L, Blanchet P, et al
Metabolic syndrome and prostate cancer in Afro-Caribbean men.
Prostate. 2021 Dec 14:e24281. doi: 10.1002/pros.24281.
PubMed Abstract available

POCKROS B, Stensland KD, Parries M, Frankenberger E, et al
Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.
PubMed Abstract available

ZAREI A, Javid H, Sanjarian S, Senemar S, et al
Metagenomics studies for the diagnosis and treatment of prostate cancer.
Prostate. 2021 Dec 2. doi: 10.1002/pros.24276.
PubMed Abstract available

MATTI B, Reeves F, Prouse M, Zargar-Shoshtari K, et al
The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers.
Prostate. 2021;81:1428-1434.
PubMed Abstract available

NAYAN M, Salari K, Bozzo A, Ganglberger W, et al
Predicting survival after radical prostatectomy: Variation of machine learning performance by race.
Prostate. 2021;81:1355-1364.
PubMed Abstract available

YAMOAH K, Asamoah FA, Abrahams AOD, Awasthi S, et al
Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
Prostate. 2021;81:1402-1410.
PubMed Abstract available

TAKEZAWA K, Fujita K, Matsushita M, Motooka D, et al
The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement.
Prostate. 2021;81:1287-1293.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant.
Prostate. 2021;81:1294-1302.
PubMed Abstract available

November 2021

NAKAYAMA H, Sekine Y, Oka D, Miyazawa Y, et al
Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Prostate. 2021 Nov 29. doi: 10.1002/pros.24274.
PubMed Abstract available

VESTRIS PG, Gourtaud G, Senechal C, Sadreux Y, et al
Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
Prostate. 2021 Nov 25. doi: 10.1002/pros.24270.
PubMed Abstract available

PLAMBECK BD, Wang LL, Mcgirr S, Jiang J, et al
Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
Prostate. 2021 Nov 22. doi: 10.1002/pros.24261.
PubMed Abstract available

PREISSER F, Wurnschimmel C, Pose RM, Heinze A, et al
Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
Prostate. 2021 Nov 22. doi: 10.1002/pros.24268.
PubMed Abstract available

NAKAZAWA M, Fang M, H Marshall C, Lotan TL, et al
Clinical and genomic features of SPOP-mutant prostate cancer.
Prostate. 2021 Nov 15. doi: 10.1002/pros.24269.
PubMed Abstract available

TRYGGESTAD AMA, Axcrona K, Axcrona U, Bigalke I, et al
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
Prostate. 2021 Nov 11. doi: 10.1002/pros.24267.
PubMed Abstract available

HANSKE J, Risse Y, Roghmann F, Pucheril D, et al
Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
Prostate. 2021 Nov 3. doi: 10.1002/pros.24264.
PubMed Abstract available

MIYAHIRA AK, Zarif JC, Coombs CC, Flavell RR, et al
Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
Prostate. 2021 Nov 3. doi: 10.1002/pros.24262.
PubMed Abstract available

October 2021

SHI Z, Lu L, Resurreccion WK, Yang W, et al
Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
Prostate. 2021 Oct 21. doi: 10.1002/pros.24252.
PubMed Abstract available

PILLING A, Kim SH, Hwang C
Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Prostate. 2021 Oct 21. doi: 10.1002/pros.24257.
PubMed Abstract available

LUO LS, Jiang JF, Luan HH, Zi H, et al
Spatial and temporal patterns of prostate cancer burden and their association with Socio-Demographic Index in Asia, 1990-2019.
Prostate. 2021 Oct 18. doi: 10.1002/pros.24258.
PubMed Abstract available

KIM S, Li L, Zhang J, Jiang C, et al
Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
Prostate. 2021 Oct 18. doi: 10.1002/pros.24256.
PubMed Abstract available

HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.
PubMed Abstract available

WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.
PubMed Abstract available

IKEUCHI W, Wakita Y, Zhang G, Li C, et al
AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.
Prostate. 2021 Oct 11. doi: 10.1002/pros.24251.
PubMed Abstract available

JIMBO M, Andrews JR, Ahmed ME, Dundar A, et al
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
Prostate. 2021 Oct 11. doi: 10.1002/pros.24246.
PubMed Abstract available

PREBAY ZJ, Medairos R, Doolittle J, Langenstroer P, et al
The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy.
Prostate. 2021;81:1064-1070.
PubMed Abstract available

September 2021

YIN Y, Liu Q, Shao Y, He X, et al
Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
Prostate. 2021 Sep 30. doi: 10.1002/pros.24245.
PubMed Abstract available

YU C, Niu L, Li L, Li T, et al
Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Prostate. 2021 Sep 30. doi: 10.1002/pros.24229.
PubMed Abstract available

YANAGISAWA T, Kimura T, Mori K, Suzuki H, et al
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Prostate. 2021 Sep 24. doi: 10.1002/pros.24243.
PubMed Abstract available

YONEYAMA T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, et al
Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
Prostate. 2021 Sep 21. doi: 10.1002/pros.24239.
PubMed Abstract available

HERNANDEZ-LLODRA S, Segales L, Juanpere N, Marta Lorenzo T, et al
SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Prostate. 2021 Sep 17. doi: 10.1002/pros.24218.
PubMed Abstract available

HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.
PubMed Abstract available

JIMENEZ-ALCAIDE E, Garcia-Fuentes C, Hernandez V, De la Pena E, et al
Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24232.
PubMed Abstract available

LETHONGSAVARN V, Pinault M, Diedhiou A, Guimaraes C, et al
Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24234.
PubMed Abstract available

AYDOS U, Cetin S, Akdemir UO, Budak FC, et al
The role of histopathological and biochemical parameters for predicting metastatic disease on (68) Ga-PSMA-11 PET in prostate cancer.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24231.
PubMed Abstract available

WATANABE R, Maekawa M, Kiyoi T, Kurata M, et al
PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24237.
PubMed Abstract available

LIU Y, Dong Y, Liu J, Zhang X, et al
Comparison between (18) F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24230.
PubMed Abstract available

CHHATRE S, Malkowicz SB, Jayadevappa R
Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24228.
PubMed Abstract available

SOKOLOVA AO, Marshall CH, Lozano R, Gulati R, et al
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24236.
PubMed Abstract available

CHO MC, Yoo S, Choo MS, Son H, et al
Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
Prostate. 2021 Sep 13. doi: 10.1002/pros.24222.
PubMed Abstract available

MANGOSH TL, Grabowska MM, Taylor DJ
SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
Prostate. 2021 Sep 7. doi: 10.1002/pros.24225.
PubMed Abstract available

MATSUDA T, Miyata Y, Nakamura Y, Otsubo A, et al
Pathological significance and prognostic role of LATS2 in prostate cancer.
Prostate. 2021 Sep 7. doi: 10.1002/pros.24226.
PubMed Abstract available

MIYAHIRA AK, Soule HR
The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
Prostate. 2021 Sep 1. doi: 10.1002/pros.24211.
PubMed Abstract available

SUMAN S, Parghane RV, Joshi A, Prabhash K, et al
Combined (177) Lu-PSMA-617 PRLT and abiraterone acetate versus (177) Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.
Prostate. 2021 Sep 1. doi: 10.1002/pros.24219.
PubMed Abstract available

EKSI M, Evren I, Akkas F, Arikan Y, et al
Machine learning algorithms can more efficiently predict biochemical recurrence after robot-assisted radical prostatectomy.
Prostate. 2021;81:913-920.
PubMed Abstract available

IAKYMENKO OA, Lugo I, Briski LM, Nemov I, et al
Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
Prostate. 2021;81:866-873.
PubMed Abstract available

MARTINEZ O, Murphy C, Bsatee A, Abaza R, et al
Impact of median lobe on urinary function after robotic prostatectomy.
Prostate. 2021;81:832-837.
PubMed Abstract available

LONERGAN PE, Cowan JE, Washington SL 3rd, Greenberg SA, et al
Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
Prostate. 2021;81:1009-1017.
PubMed Abstract available

SANCHES BDA, Maldarine JS, Vilamaior PSL, Felisbino SL, et al
Stromal cell interplay in prostate development, physiology, and pathological conditions.
Prostate. 2021;81:926-937.
PubMed Abstract available

WEE CE, Costello BA, Orme JJ, Quevedo JF, et al
Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
Prostate. 2021;81:938-943.
PubMed Abstract available

August 2021

LEDET EM, Sartor O
Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
Prostate. 2021 Aug 31. doi: 10.1002/pros.24221.
PubMed

DI MAIDA F, Grosso AA, Minervini A
Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
Prostate. 2021 Aug 31. doi: 10.1002/pros.24220.
PubMed

SHAO L, Wang J, Karatas O, Ittmann M, et al
MEX3D is an oncogenic driver in prostate cancer.
Prostate. 2021 Aug 29. doi: 10.1002/pros.24216.
PubMed Abstract available

SUN BL
Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Prostate. 2021 Aug 26. doi: 10.1002/pros.24213.
PubMed Abstract available

WANG Z, Zhu S, Zhao J, Nie L, et al
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Prostate. 2021 Aug 26. doi: 10.1002/pros.24215.
PubMed Abstract available

OKINAKA Y, Kageyama S, Nishizawa K, Yoshida T, et al
Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.
Prostate. 2021 Aug 21. doi: 10.1002/pros.24212.
PubMed Abstract available

HAFFNER MC, Bhamidipati A, Tsai HK, Esopi DM, et al
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
Prostate. 2021 Aug 16. doi: 10.1002/pros.24210.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Nocera L, Ruvolo CC, et al
The effect of primary urological cancers on survival in men with secondary prostate cancer.
Prostate. 2021 Aug 16. doi: 10.1002/pros.24209.
PubMed Abstract available

NANDALUR KR, Colvin R, Walker D, Nandalur SR, et al
Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics.
Prostate. 2021 Aug 10. doi: 10.1002/pros.24207.
PubMed Abstract available

WURNSCHIMMEL C, Wenzel M, Wang N, Tian Z, et al
Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.
Prostate. 2021;81:785-793.
PubMed Abstract available

WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.
Prostate. 2021;81:778-784.
PubMed Abstract available

WAGASKAR VG, Ratnani P, Levy M, Moody K, et al
Clinical characteristics and oncological outcomes in negative multiparametric MRI patients undergoing robot-assisted radical prostatectomy.
Prostate. 2021;81:772-777.
PubMed Abstract available

July 2021

ROSSIGNOL T, Gourtaud G, Senechal C, Sadreux Y, et al
Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
Prostate. 2021 Jul 28. doi: 10.1002/pros.24206.
PubMed Abstract available

LEIS-FILHO AF, Lainetti PD, Kobayashi PE, Palmieri C, et al
Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer.
Prostate. 2021 Jul 28. doi: 10.1002/pros.24199.
PubMed Abstract available

CAO Y, Zhang W, Li Y, Fu J, et al
Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
Prostate. 2021 Jul 28. doi: 10.1002/pros.24204.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients.
Prostate. 2021 Jul 26. doi: 10.1002/pros.24202.
PubMed Abstract available

CHAO OS, Goodman OB Jr
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Prostate. 2021 Jul 23. doi: 10.1002/pros.24200.
PubMed Abstract available

EPSTEIN JI
Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.
PubMed

WEI J, Yang W, Shi Z, Lu L, et al
Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
PubMed Abstract available

FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
PubMed Abstract available

LIU G, Zhu Y, Yao Z, Jiang Y, et al
Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
PubMed Abstract available

HUANG D, Ruan X, Wu Y, Lin X, et al
Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
PubMed Abstract available

LAUNER BM, Lloyd GL
Sociodemographic index and global trends in prostate cancer: 1990-2017.
Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
PubMed Abstract available

CHEN DY, Su PJ, See LC, Liu JR, et al
Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Prostate. 2021 Jul 1. doi: 10.1002/pros.24187.
PubMed Abstract available

BROGGI G, Lo Giudice A, Di Mauro M, Asmundo MG, et al
SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).
Prostate. 2021 Jul 1. doi: 10.1002/pros.24185.
PubMed Abstract available

CORRADI JP, Cumarasamy CW, Staff I, Tortora J, et al
Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
Prostate. 2021;81:694-702.
PubMed Abstract available

June 2021

LV S, Pu X, Luo M, Wen H, et al
Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells.
Prostate. 2021 Jun 29. doi: 10.1002/pros.24186.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Ruvolo CC, Nocera L, et al
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores.
Prostate. 2021 Jun 29. doi: 10.1002/pros.24184.
PubMed Abstract available

LENDINEZ-CANO G, Ojeda-Claro AV, Gomez-Gomez E, Morales Jimenez P, et al
Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naive patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
Prostate. 2021 Jun 29. doi: 10.1002/pros.24182.
PubMed Abstract available

BASU HS, Wilganowski N, Robertson S, Reuben JM, et al
Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
Prostate. 2021 Jun 25. doi: 10.1002/pros.24146.
PubMed Abstract available

NUNES-XAVIER CE, Kildal W, Kleppe A, Danielsen HE, et al
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.
PubMed Abstract available

WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
PubMed Abstract available

FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
PubMed Abstract available

WANG L, Li H, Li Z, Li M, et al
Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Prostate. 2021;81:508-520.
PubMed Abstract available

NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Prostate. 2021;81:572-579.
PubMed Abstract available

WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates.
Prostate. 2021;81:443-451.
PubMed Abstract available

CIPOLLARI S, Jamshidi N, Du L, Sung K, et al
Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.
Prostate. 2021;81:521-529.
PubMed Abstract available

XIAO GQ, Ho G, Suen C, Hurth KM, et al
Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
Prostate. 2021;81:469-477.
PubMed Abstract available

May 2021

LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
Barriers and facilitators of germline genetic evaluation for prostate cancer.
Prostate. 2021 May 31. doi: 10.1002/pros.24172.
PubMed Abstract available

QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
Prostate. 2021 May 31. doi: 10.1002/pros.24173.
PubMed Abstract available

SI S, Zheng B, Wang Z, Niu Z, et al
Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
Prostate. 2021 May 31. doi: 10.1002/pros.24170.
PubMed Abstract available

MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
Prostate. 2021 May 25. doi: 10.1002/pros.24171.
PubMed Abstract available

ZHU S, Chen J, Ni Y, Zhang H, et al
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
Prostate. 2021 May 24. doi: 10.1002/pros.24167.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
Prostate. 2021 May 19. doi: 10.1002/pros.24169.
PubMed Abstract available

FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
The end of "very low risk" in localized prostate cancer?
Prostate. 2021 May 19. doi: 10.1002/pros.24168.
PubMed

SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
Prostate. 2021 May 12. doi: 10.1002/pros.24143.
PubMed Abstract available

XU J, Isaacs WB, Mamawala M, Shi Z, et al
Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
Prostate. 2021 May 6. doi: 10.1002/pros.24140.
PubMed Abstract available

BANERJEE M, Li Z, Gao Y, Lai F, et al
Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
Prostate. 2021 May 6. doi: 10.1002/pros.24144.
PubMed Abstract available

WANG V, Geybels MS, Jordahl KM, Gerke T, et al
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Prostate. 2021 May 6. doi: 10.1002/pros.24148.
PubMed Abstract available

DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
Prostate. 2021 May 5. doi: 10.1002/pros.24139.
PubMed Abstract available

CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
Prostate. 2021 May 5. doi: 10.1002/pros.24136.
PubMed Abstract available

ONAL C, Ozyigit G, Oymak E, Guler OC, et al
Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
Prostate. 2021 May 5. doi: 10.1002/pros.24142.
PubMed Abstract available

WENZEL M, Wurnschimmel C, Nocera L, Colla Ruvolo C, et al
The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.
Prostate. 2021;81:339-346.
PubMed Abstract available

LEON P, Cancel-Tassin G, Bourdon V, Buecher B, et al
Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
Prostate. 2021;81:318-325.
PubMed Abstract available

ZHAO H, Howard LE, De Hoedt AM, Terris MK, et al
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Prostate. 2021;81:390-397.
PubMed Abstract available

April 2021

TAN B, Chen X, Fan Y, Yang Y, et al
STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
PubMed Abstract available

BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
(225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
PubMed Abstract available

QU F, Gu Y, Xue M, He M, et al
Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
PubMed Abstract available

HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
PubMed Abstract available

BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
PubMed Abstract available

ONAL C, Kose F, Ozyigit G, Aksoy S, et al
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
PubMed Abstract available

BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
PubMed Abstract available

THULIN MH, Maatta J, Linder A, Sterbova S, et al
Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
PubMed Abstract available

WANG Y, Wu G, Fan L, Pan J, et al
The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
PubMed Abstract available

LEDET EM, Burgess EF, Sokolova AO, Jaeger EB, et al
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Prostate. 2021 Apr 1. doi: 10.1002/pros.24123.
PubMed Abstract available

March 2021

SABOL RA, Ledet EM, Jaeger E, Hatton W, et al
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
Prostate. 2021 Mar 24. doi: 10.1002/pros.24120.
PubMed Abstract available

CHOI Y, Smith KC, Shukla A, Blackford AL, et al
What are survivorship care plans failing to tell men after prostate cancer treatment?
Prostate. 2021 Mar 23. doi: 10.1002/pros.24116.
PubMed Abstract available

GRAHAM LS, True LD, Gulati R, Schade GR, et al
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Prostate. 2021 Mar 23. doi: 10.1002/pros.24118.
PubMed Abstract available

LEHTO TK, Sturenberg C, Malen A, Erickson AM, et al
Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
Prostate. 2021 Mar 18. doi: 10.1002/pros.24108.
PubMed Abstract available

LIOTTI A, La Civita E, Cennamo M, Crocetto F, et al
Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform.
Prostate. 2021 Mar 18. doi: 10.1002/pros.24117.
PubMed Abstract available

ZHENG X, Xu H, Gong L, Cao D, et al
Vinculin orchestrates prostate cancer progression by regulating tumor cell invasion, migration, and proliferation.
Prostate. 2021 Mar 12. doi: 10.1002/pros.24113.
PubMed Abstract available

ATEEQ B, Kunju LP, Carskadon SL, Pandey SK, et al
Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Prostate. 2021 Mar 8. doi: 10.1002/pros.24111.
PubMed

SWANSON GP, Lenz L, Stone S, Cohen T, et al
Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
Prostate. 2021;81:261-267.
PubMed Abstract available

TAN YG, Khalid F, Huang HH, Chen K, et al
Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.
Prostate. 2021;81:242-251.
PubMed Abstract available

LI Y, Ge C, Franceschi RT
Role of Runx2 in prostate development and stem cell function.
Prostate. 2021;81:231-241.
PubMed Abstract available

February 2021

SHENDEROV E, Boudadi K, Fu W, Wang H, et al
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Prostate. 2021 Feb 26. doi: 10.1002/pros.24110.
PubMed Abstract available

WETTSTEIN MS, David LA, Pazhepurackel C, Qureshi AA, et al
Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis.
Prostate. 2021 Feb 18. doi: 10.1002/pros.24105.
PubMed Abstract available

TAO LJ, Pan XY, Wang JW, Zhang L, et al
Circular RNA circANKS1B acts as a sponge for miR-152-3p and promotes prostate cancer progression by upregulating TGF-alpha expression.
Prostate. 2021 Feb 8. doi: 10.1002/pros.24102.
PubMed Abstract available

LEE JM, Kim U, Yang H, Ryu B, et al
TALEN-mediated generation of Nkx3.1 knockout rat model.
Prostate. 2021;81:182-193.
PubMed Abstract available

January 2021

NAITO R, Kano H, Shimada T, Makino T, et al
A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
Prostate. 2021 Jan 25. doi: 10.1002/pros.24106.
PubMed Abstract available

EMAM A, Hermann G, Attwood K, Ji W, et al
Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer.
Prostate. 2021 Jan 20. doi: 10.1002/pros.24089.
PubMed Abstract available

VLACHOSTERGIOS PJ, Niaz MJ, Skafida M, Mosallaie SA, et al
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted beta-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Prostate. 2021 Jan 19. doi: 10.1002/pros.24104.
PubMed Abstract available

LIU JM, Lin CC, Chen MF, Liu KL, et al
Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
Prostate. 2021 Jan 4. doi: 10.1002/pros.24096.
PubMed Abstract available

ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Prostate. 2021;81:81-88.
PubMed Abstract available

December 2020

IMAMURA R, Kitagawa S, Kubo T, Irie A, et al
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
Prostate. 2020 Dec 24. doi: 10.1002/pros.24090.
PubMed Abstract available

COUGHLIN SS, Vernon M, Klaassen Z, Tingen MS, et al
Knowledge of prostate cancer among African American men: A systematic review.
Prostate. 2020 Dec 23. doi: 10.1002/pros.24097.
PubMed Abstract available

KAZUNO S, Fujimura T, Fujime M, Miura Y, et al
O-glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer.
Prostate. 2020 Dec 21. doi: 10.1002/pros.24094.
PubMed Abstract available

ZHANG Y, Mou Y, Liang C, Zhu S, et al
Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.
Prostate. 2020 Dec 18. doi: 10.1002/pros.24092.
PubMed Abstract available

ZHOU Y, Mai Z, Yan W, Chen Y, et al
The characteristics and spatial distributions of prostate cancer in autopsy specimens.
Prostate. 2020 Dec 11. doi: 10.1002/pros.24091.
PubMed Abstract available

ZHANG Y, Guo Z, Du T, Chen J, et al
Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
Prostate. 2020 Dec 11. doi: 10.1002/pros.24093.
PubMed

SHEIKHBAHAEI S, Reyes DK, Rowe SP, Pienta KJ, et al
CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naive oligometastatic prostate cancer.
Prostate. 2020 Dec 1. doi: 10.1002/pros.24088.
PubMed Abstract available

GREENLAND NY, Cowan JE, Chan E, Carroll PR, et al
Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category.
Prostate. 2020;80:1421-1428.
PubMed Abstract available

LI W, Bicak M, Sjoberg DD, Vertosick E, et al
Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.
Prostate. 2020;80:1405-1412.
PubMed Abstract available

November 2020

SHIH HJ, Fang SC, An L, Shao YJ, et al
Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality.
Prostate. 2020 Nov 5. doi: 10.1002/pros.24087.
PubMed Abstract available

YAMOAH K, Lal P, Awasthi S, Naghavi AO, et al
TMPRSS2-ERG fusion impact anterior tumor location in men with prostate cancer.
Prostate. 2020 Nov 3. doi: 10.1002/pros.24086.
PubMed Abstract available

DEEK M, Lilleby W, Vaage V, Hole KH, et al
Impact of radiation dose on recurrence in high-risk prostate cancer patients.
Prostate. 2020;80:1322-1327.
PubMed Abstract available

BLACK MH, Li S, LaDuca H, Lo MT, et al
Validation of a prostate cancer polygenic risk score.
Prostate. 2020;80:1314-1321.
PubMed Abstract available

October 2020

JARRARD D, Filon M, Huang W, Havighurst T, et al
A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.
Prostate. 2020 Oct 23. doi: 10.1002/pros.24076.
PubMed Abstract available

YANG Y, Attwood K, Bshara W, Mohler JL, et al
High intratumoral CD8(+) T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy.
Prostate. 2020 Oct 21. doi: 10.1002/pros.24068.
PubMed Abstract available

MIYAHIRA AK, Soule HR
The 26th Annual Prostate Cancer Foundation Scientific Retreat Report.
Prostate. 2020 Oct 21. doi: 10.1002/pros.24083.
PubMed Abstract available

WASHINGTON SL 3RD, Cowan JE, Herlemann A, Zuniga KB, et al
Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
Prostate. 2020 Oct 19. doi: 10.1002/pros.24085.
PubMed Abstract available

AMELOT A, Terrier LM, Le Nail LR, Cristini J, et al
Spine metastasis in patients with prostate cancer: Survival prognosis assessment.
Prostate. 2020 Oct 16. doi: 10.1002/pros.24084.
PubMed Abstract available

IWAMOTO H, Izumi K, Shimada T, Kano H, et al
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
Prostate. 2020 Oct 13. doi: 10.1002/pros.24082.
PubMed Abstract available

DING Y, Lee M, Gao Y, Bu P, et al
Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance.
Prostate. 2020 Oct 6. doi: 10.1002/pros.24081.
PubMed Abstract available

HERTZOG JR, Zhang Z, Bignan G, Connolly PJ, et al
AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
Prostate. 2020;80:1223-1232.
PubMed Abstract available

MONTES M, MacKenzie L, McAllister MJ, Roseweir A, et al
Determining the prognostic significance of IKKalpha in prostate cancer.
Prostate. 2020;80:1188-1202.
PubMed Abstract available

September 2020

VICIER C, Ravi P, Kwak L, Werner L, et al
Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Prostate. 2020 Sep 28. doi: 10.1002/pros.24079.
PubMed Abstract available

OMRI N, Kamil M, Alexander K, Alexander K, et al
Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
Prostate. 2020 Sep 24. doi: 10.1002/pros.24078.
PubMed Abstract available

LEE BS, Chu SY, Jung WJ, Jeong HJ, et al
(18) F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.
Prostate. 2020 Sep 22. doi: 10.1002/pros.24062.
PubMed Abstract available

VILSON FL, Li S, Brooks JD, Eisenberg ML, et al
Sudden PSA rise to >/=20 ng/ml and prostate cancer diagnosis in the United States: A population-based study.
Prostate. 2020 Sep 21. doi: 10.1002/pros.24075.
PubMed Abstract available

HARSHMAN LC, Wang VX, Hamid AA, Santone G, et al
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Prostate. 2020 Sep 19. doi: 10.1002/pros.24074.
PubMed Abstract available

NAITO Y, Kato M, Kawanishi H, Yuguchi Y, et al
The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Prostate. 2020 Sep 11. doi: 10.1002/pros.24069.
PubMed Abstract available

DUBEY B, Jackson M, Zeigler-Johnson C, Devarajan K, et al
Interactive effect of TLR SNPs and exposure to sexually transmitted infections on prostate cancer risk in Jamaican men.
Prostate. 2020 Sep 7. doi: 10.1002/pros.24067.
PubMed Abstract available

ZHANG M, Wang Q, Sun X, Yin Q, et al
beta2 -adrenergic receptor signaling drives prostate cancer progression by targeting the Sonic hedgehog-Gli1 signaling activation.
Prostate. 2020 Sep 7. doi: 10.1002/pros.24060.
PubMed Abstract available

KAUR H, Samarska I, Lu J, Faisal F, et al
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Prostate. 2020;80:1012-1023.
PubMed Abstract available

ANGEL PM, Spruill L, Jefferson M, Bethard JR, et al
Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.
Prostate. 2020;80:1071-1086.
PubMed Abstract available

August 2020

MIYAHIRA AK, Pienta KJ, Babich JW, Bander NH, et al
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
Prostate. 2020 Aug 31. doi: 10.1002/pros.24056.
PubMed Abstract available

MCALLISTER M, Constancio V, Patek S, Gan H, et al
Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naive prostate cancer.
Prostate. 2020 Aug 26. doi: 10.1002/pros.24064.
PubMed Abstract available

WIGGINS EK, Oyekunle T, Howard LE, Markt SC, et al
Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial.
Prostate. 2020 Aug 24. doi: 10.1002/pros.24052.
PubMed Abstract available

LIU W, Hou J, Petkewicz J, Na R, et al
Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
Prostate. 2020 Aug 17. doi: 10.1002/pros.24057.
PubMed Abstract available

SHORE ND, Drake CG, Lin DW, Ryan CJ, et al
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Prostate. 2020 Aug 11. doi: 10.1002/pros.24053.
PubMed Abstract available

DI BELLA CM, Howard LE, Oyekunle T, De Hoedt AM, et al
Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy.
Prostate. 2020 Aug 7. doi: 10.1002/pros.24054.
PubMed Abstract available

SIMONS BW, Dalrymple S, Rosen M, Zheng L, et al
A hemi-spleen injection model of liver metastasis for prostate cancer.
Prostate. 2020 Aug 6. doi: 10.1002/pros.24055.
PubMed Abstract available

NAEEM A, Dakshanamurthy S, Walthieu H, Parasido E, et al
Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells.
Prostate. 2020 Aug 6. doi: 10.1002/pros.24050.
PubMed Abstract available

July 2020

AHMED ME, Andrews JR, Alamiri J, Higa J, et al
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Prostate. 2020 Jul 31. doi: 10.1002/pros.24048.
PubMed Abstract available

NANDA JS, Awadallah WN, Kohrt SE, Popovics P, et al
Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
Prostate. 2020 Jul 21. doi: 10.1002/pros.24019.
PubMed Abstract available

FERRARI MG, Ganaie AA, Shabenah A, Mansini AP, et al
Identifying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: An aggressive cancer subtype prevalent in African American patients.
Prostate. 2020 Jul 20. doi: 10.1002/pros.24018.
PubMed Abstract available

DEE EC, Nezolosky MD, Chipidza FE, Arega MA, et al
Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities.
Prostate. 2020 Jul 13. doi: 10.1002/pros.24041.
PubMed Abstract available

ABUDUREXITI M, Zhu W, Wang Y, Wang J, et al
Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Prostate. 2020 Jul 10. doi: 10.1002/pros.24027.
PubMed Abstract available

ERICKSON AM, Lokman U, Lahdensuo K, Tornberg S, et al
PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer.
Prostate. 2020 Jul 7. doi: 10.1002/pros.24040.
PubMed Abstract available

ZHAN B, Huang L, Chen Y, Ye W, et al
miR-196a-mediated downregulation of p27(kip1) protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy.
Prostate. 2020 Jul 6. doi: 10.1002/pros.24036.
PubMed Abstract available

FEDERER-GSPONER JR, Muller DC, Zellweger T, Eggimann M, et al
Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.
Prostate. 2020 Jul 6. doi: 10.1002/pros.24039.
PubMed Abstract available

QIN C, Sheng Z, Huang X, Tang J, et al
Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
Prostate. 2020 Jul 6. doi: 10.1002/pros.24042.
PubMed Abstract available

BONK S, Kluth M, Jansen K, Hube-Magg C, et al
Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
Prostate. 2020 Jul 6. doi: 10.1002/pros.24038.
PubMed Abstract available

TANG M, Gao S, Zhang L, Liu B, et al
Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Prostate. 2020;80:742-752.
PubMed Abstract available

RINELLA L, Pizzo B, Frairia R, Delsedime L, et al
Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression.
Prostate. 2020 Jul 1. doi: 10.1002/pros.24037.
PubMed Abstract available

June 2020

CHEN Y, Li X, Mamouni K, Yang Y, et al
Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer.
Prostate. 2020 Jun 19. doi: 10.1002/pros.24032.
PubMed Abstract available

MAESHIGE N, Kitagawa K, Yamasaki S, Ishii A, et al
Can ultrasound irradiation be a therapeutic option for prostate cancer?
Prostate. 2020 Jun 18. doi: 10.1002/pros.24030.
PubMed Abstract available

BEGEMANN D, Wang Y, Yang W, Kyprianou N, et al
Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Prostate. 2020 Jun 16. doi: 10.1002/pros.24015.
PubMed Abstract available

WANG K, Chen Z, Shi J, Feng Y, et al
Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells.
Prostate. 2020 Jun 15. doi: 10.1002/pros.24029.
PubMed Abstract available

TAYLOR RA, Farrelly SG, Clark AK, Watt MJ, et al
Early intervention exercise training does not delay prostate cancer progression in Pten(-/-) mice.
Prostate. 2020 Jun 10. doi: 10.1002/pros.24024.
PubMed Abstract available

ELHODAKY M, Hong LK, Kadkol S, Diamond AM, et al
Selenium-binding protein 1 alters energy metabolism in prostate cancer cells.
Prostate. 2020 Jun 8. doi: 10.1002/pros.24028.
PubMed Abstract available

CHADID S, Barber JR, Nelson WG, Gurel B, et al
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.
Prostate. 2020 Jun 7. doi: 10.1002/pros.24023.
PubMed Abstract available

CARSON JJK, Di Lena MA, Berman DM, Siemens DR, et al
Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer.
Prostate. 2020 Jun 7. doi: 10.1002/pros.24025.
PubMed Abstract available

RII J, Sakamoto S, Yamada Y, Takeshita N, et al
Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
Prostate. 2020 Jun 5. doi: 10.1002/pros.24016.
PubMed Abstract available

CHEN X, Chen F, Ren Y, Weng G, et al
Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
Prostate. 2020;80:727.
PubMed

OJALILL M, Virtanen N, Rappu P, Siljamaki E, et al
Interaction between prostate cancer cells and prostate fibroblasts promotes accumulation and proteolytic processing of basement membrane proteins.
Prostate. 2020;80:715-726.
PubMed Abstract available

ITSUMI M, Shiota M, Sekino Y, Ushijima M, et al
High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer.
Prostate. 2020 Jun 1. doi: 10.1002/pros.24022.
PubMed Abstract available

ELSHAFAE SM, Dirksen WP, Alasonyalilar-Demirer A, Breitbach J, et al
Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
Prostate. 2020;80:698-714.
PubMed Abstract available

PALANGMONTHIP W, Wu R, Tarima S, Bobholz SA, et al
Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer.
Prostate. 2020;80:687-697.
PubMed Abstract available

May 2020

LINDER A, Larsson K, Welen K, Damber JE, et al
RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Prostate. 2020 May 25. doi: 10.1002/pros.23994.
PubMed Abstract available

TABEI T, Taguri M, Sakai N, Koh H, et al
Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
Prostate. 2020 May 20. doi: 10.1002/pros.23997.
PubMed Abstract available

SHI X, Sun J, Li H, Lin H, et al
Antitumor efficacy of interferon-gamma-modified exosomal vaccine in prostate cancer.
Prostate. 2020 May 19. doi: 10.1002/pros.23996.
PubMed Abstract available

HOU Y, Li H, Huo W
THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
Prostate. 2020 May 18. doi: 10.1002/pros.23989.
PubMed Abstract available

LIU Z, Murphy SF, Huang J, Zhao L, et al
A novel immunocompetent model of metastatic prostate cancer-induced bone pain.
Prostate. 2020 May 14. doi: 10.1002/pros.23993.
PubMed Abstract available

LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study.
Prostate. 2020 May 5. doi: 10.1002/pros.23991.
PubMed Abstract available

LIU S, Liu F, Zhang B, Yan P, et al
CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion.
Prostate. 2020 May 1. doi: 10.1002/pros.23990.
PubMed Abstract available

SU X, Long Q, Bo J, Shi Y, et al
Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
Prostate. 2020;80:508-517.
PubMed Abstract available

GLEAVE AM, Ci X, Lin D, Wang Y, et al
A synopsis of prostate organoid methodologies, applications, and limitations.
Prostate. 2020;80:518-526.
PubMed Abstract available

GREENLAND NY, Cowan JE, Zhang L, Carroll PR, et al
Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.
Prostate. 2020;80:653-659.
PubMed Abstract available

April 2020

SEBBEN M, Tafuri A, Porcaro AB, Artibani W, et al
Response to: Bando et al. Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histological and molecular analyses.
Prostate. 2020 Apr 23. doi: 10.1002/pros.23987.
PubMed

LI X, Jiao M, Hu J, Qi M, et al
miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
Prostate. 2020 Apr 15. doi: 10.1002/pros.23979.
PubMed Abstract available

CHENG Y, Wang D, Jiang J, Huang W, et al
Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
Prostate. 2020 Apr 13. doi: 10.1002/pros.23976.
PubMed Abstract available

March 2020

LEU WJ, Wang CT, Hsu JL, Chen IS, et al
Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na(+) /K(+) -ATPase internalization and tubulin acetylation.
Prostate. 2020;80:305-318.
PubMed Abstract available

WU Z, Wang K, Yang Z, Pascal LE, et al
A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR(F876L) nuclear import and function.
Prostate. 2020;80:319-328.
PubMed Abstract available

February 2020

ERDEM S, Verep S, Bagbudar S, Ozluk Y, et al
The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
Prostate. 2020;80:225-234.
PubMed Abstract available

FAGERLAND ST, Hill DK, van Wamel A, de Lange Davies C, et al
Ultrasound and magnetic resonance imaging for group stratification and treatment monitoring in the transgenic adenocarcinoma of the mouse prostate model.
Prostate. 2020;80:186-197.
PubMed Abstract available

TAYLOR AS, Morgan TM, Wallington DG, Chinnaiyan AM, et al
Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
Prostate. 2020;80:146-152.
PubMed Abstract available

THOMAS-JARDIN SE, Dahl H, Kanchwala MS, Ha F, et al
RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Prostate. 2020;80:133-145.
PubMed Abstract available

WANG R, Lewis MS, Lyu J, Zhau HE, et al
Cancer-stromal cell fusion as revealed by fluorescence protein tracking.
Prostate. 2020;80:274-283.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: